Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer

PURPOSE: Alectinib is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor that is active in the central nervous system (CNS). Alectinib demonstrated robust efficacy in a pooled analysis of two single-arm, open-label phase II studies (NP28673, NCT01801111; NP28761, NCT01871805) in crizo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Morcos, Peter N., Nueesch, Eveline, Jaminion, Felix, Guerini, Elena, Hsu, Joy C., Bordogna, Walter, Balas, Bogdana, Mercier, Francois
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6010493/
https://ncbi.nlm.nih.gov/pubmed/29748847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3597-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados